Patents by Inventor Yuping Zhu
Yuping Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959817Abstract: An electromagnetic ultrasonic double wave transducer, comprising a shell (1), and a permanent magnet assembly, a coil (4), a shielding layer (5), and a wire (6) which are provided in the shell (1). The permanent magnet assembly comprises a first permanent magnet (2) and a second permanent magnet (3) sleeved on the first permanent magnet (2). The magnetizing directions of the first permanent magnet (2) and the second permanent magnet (3) are perpendicular to the bottom of the shell (1), and the magnetic field directions of the first permanent magnet (2) and the second permanent magnet (3) are opposite. A non-conducting non-magnetic bushing material (9) is provided between the first permanent magnet (2) and the second permanent magnet (3), and upper end faces of the first permanent magnet (2) and the second permanent magnet (3) realize magnetic circuit closing by means of a magnetic circuit closing element (8).Type: GrantFiled: October 26, 2018Date of Patent: April 16, 2024Assignee: SUZHOU PHASERISE TECHNOLOGY CO., LTD.Inventors: Long Yang, Mingming Xie, Yisheng Jin, Xinzong Zhou, Junhui Zhao, Xuxiang Zhu, Yuping Shen
-
Publication number: 20240067869Abstract: The present disclosure relates to a fracturing propping agent and a preparation method thereof. The fracturing propping agent comprises the following raw materials: dry sludge, quartz sand, coal ash, bauxite and clay.Type: ApplicationFiled: November 11, 2022Publication date: February 29, 2024Inventors: Changming Su, Zhanqing Qu, Xinwu Zhu, Zuochen Li, Yuping Fan, Wei Liu, Wen Su, Kai Weng
-
Patent number: 11820805Abstract: The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile.Type: GrantFiled: December 13, 2018Date of Patent: November 21, 2023Assignee: MERCK SHARP & DOHME LLCInventors: Lin Yan, Pei Huo, Ahmet Kekec, Danqing D. Feng, Yuping Zhu, Dmitri Pissarnitski, Chris Moyes, Songnian Lin
-
Publication number: 20230310551Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: August 24, 2021Publication date: October 5, 2023Applicant: Merck Sharp & Dohme LLCInventors: Christina B. Madsen-Duggan, Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Ravi Nargund, Christopher R. Moyes, Dmitri A. Pissarnitski, Zhicai Shi, Zhicai Wu, Lin Yan, Yuping Zhu
-
Publication number: 20230225859Abstract: A semi-loaded intralocular lens injector device and related methods are described. In some embodiments, an intraocular lens is stored in a non-deformed configuration in a cassette separate from the injector device. When the cassette is inserted into a cavity of the injector device, a projection extending into the cavity deforms the intraocular lens into a predetermined configuration.Type: ApplicationFiled: January 18, 2023Publication date: July 20, 2023Applicant: Beaver-Visitec International, Inc.Inventors: Nathan Stewart Cauldwell, Paula Yowen Wang, Alexander Yuping Zhu
-
Patent number: 11566057Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.Type: GrantFiled: September 21, 2018Date of Patent: January 31, 2023Assignee: Merck Sharp & Dohme LLCInventors: Anandan Palani, Qiaolin Deng, Chunhui Huang, Yuping Zhu, Elisabetta Bianchi, Federica Orvieto
-
Publication number: 20220273770Abstract: Glucose-responsive insulin conjugates that contain one or more trisaccharides are provided. Such insulin conjugates may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.Type: ApplicationFiled: July 23, 2020Publication date: September 1, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, Erin N. Guidry, Pei Huo, Andrew J. Kassick, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
-
Publication number: 20220233647Abstract: Glucose-responsive insulin conjugates that contain one or more linear oligomer sugar cluster are provided. Such insulin conjugates that may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.Type: ApplicationFiled: June 1, 2020Publication date: July 28, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, Songnian Lin, Dmitri A. Pissarnitski, Brenda Pipik, Lin Yan, Yuping Zhu
-
Publication number: 20210198339Abstract: The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile.Type: ApplicationFiled: December 13, 2018Publication date: July 1, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Lin Yan, Pei Huo, Ahmet Kekec, Danqing D. Feng, Yuping Zhu, Dmitri Pissarnitski, Chris Moyes, Songnian Lin
-
Patent number: 11041009Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.Type: GrantFiled: March 19, 2018Date of Patent: June 22, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Ravi Nargund, Brenda Pipik, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
-
Publication number: 20210177981Abstract: The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain). In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.Type: ApplicationFiled: December 13, 2018Publication date: June 17, 2021Applicants: Merck Sharp & Dohme Corp., SmartCells, Inc.Inventors: Lin Yan, Pei Huo, Ahmet Kekec, Yuping Zhu, Dmitri Pissarnitski, Danqing D. Feng, Chris Moyes, Zhiqiang Zhao, David N. Hunter, Songnian Lin, Thomas M. Lancaster, Benjamin Chen
-
Patent number: 10800827Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: November 26, 2018Date of Patent: October 13, 2020Assignee: MERCK SHARP & DOHME CORP.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Publication number: 20200270325Abstract: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.Type: ApplicationFiled: September 21, 2018Publication date: August 27, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Anandan Palani, Qiaolin Deng, Chunhui Huang, Yuping Zhu, Elisabetta Bianchi, Federica Orvieto
-
Patent number: 10689430Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: May 23, 2017Date of Patent: June 23, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
-
Publication number: 20200087375Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.Type: ApplicationFiled: March 19, 2018Publication date: March 19, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, David N. Hunter, Pei Huo, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Ravi Nargund, Brenda Pipik, Dmitri A. Pissarnitski, Lin Yan, Zhiqiang Zhao, Yuping Zhu
-
Publication number: 20190177393Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: May 23, 2017Publication date: June 13, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
-
Publication number: 20190092833Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: November 26, 2018Publication date: March 28, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 10183981Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: June 13, 2018Date of Patent: January 22, 2019Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Publication number: 20180291078Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: June 13, 2018Publication date: October 11, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 10017556Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: November 19, 2015Date of Patent: July 10, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu